U.S. FDA Issues Complete Response Letter for Baricitinib

INDIANAPOLIS, April 14, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for th... Biopharmaceuticals, FDA Eli Lilly, Incyte, baricitinib, rheumatoid arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news